Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
Wuxi AppTec Co's operating assets for the quarter that ended in Mar. 2026 was $9,290 Mil. Wuxi AppTec Co's operating liabilities for the quarter that ended in Mar. 2026 was $2,070 Mil. Wuxi AppTec Co's Total Assets for the quarter that ended in Dec. 2025 was $14,641 Mil. Therefore, Wuxi AppTec Co's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2026 was 0.49.
Wuxi AppTec Co Scaled Net Operating Assets Related Terms
Wuxi AppTec Co Scaled Net Operating Assets Historical Data
* Premium members only.
The historical data trend for Wuxi AppTec Co's Scaled Net Operating Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WUXIF vs TMO, DHR, IDXX: Scaled Net Operating Assets Comparison
For the Diagnostics & Research subindustry, Wuxi AppTec Co's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wuxi AppTec Co Scaled Net Operating Assets vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Wuxi AppTec Co's Scaled Net Operating Assets distribution charts can be found below:
* The bar in red indicates where Wuxi AppTec Co's Scaled Net Operating Assets falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Scaled Net Operating Assets of 0.49 mean?
Wuxi AppTec Co (WUXIF) has a Scaled Net Operating Assets of 0.49 as of Mar. 2026. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Wuxi AppTec Co and its competitors.
Is Wuxi AppTec Co's Scaled Net Operating Assets too high?
Wuxi AppTec Co's current Scaled Net Operating Assets is 0.49. Overall, Wuxi AppTec Co has a GF Score™ of 84/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Wuxi AppTec Co's Scaled Net Operating Assets compare to TMO and DHR?
Wuxi AppTec Co's Scaled Net Operating Assets of 0.49 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Medical Diagnostics & Research company?
A good Scaled Net Operating Assets depends on the Medical Diagnostics & Research industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Wuxi AppTec Co and its competitors. Wuxi AppTec Co's current Scaled Net Operating Assets is 0.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wuxi AppTec Co stock overvalued right now?
Based on GuruFocus' analysis, Wuxi AppTec Co (WUXIF) is currently considered Significantly Overvalued. The stock's GF Value™ is $11.26, compared to a current price of $15.63 — trading 38.8% above its estimated fair value. The current Scaled Net Operating Assets is 0.49. Wuxi AppTec Co's overall GF Score™ is 84/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Wuxi AppTec Co (WUXIF), the current Scaled Net Operating Assets is 0.49 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Wuxi AppTec Co (WUXIF) Overvalued in 2026?
Based on GuruFocus' analysis, Wuxi AppTec Co stock appears to be overvalued.
The current stock price of $15.63 is trading 38.8% above its estimated GF Value™ of $11.26.
GuruFocus considers Wuxi AppTec Co to be Significantly Overvalued.
Key valuation signals for WUXIF:
Scaled Net Operating Assets: 0.49
GF Value™: $11.26 vs. price of $15.63 (38.8% above fair value)
No single metric tells the full story. See the WUXIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Wuxi AppTec Co Ltd provides a portfolio of research and manufacturing services throughout the discovery, development, and manufacturing spectrum for small molecule drugs, development of computer software and databases as well as consulting services for combinatorial chemistry and pharmaceuticals. The services offered by the company include drug research and development testing, clinical research services, an end-to-end CRDMO platform for peptide, oligonucleotide, and small molecules, and integrated biology services and solutions for drug discovery. The company's reportable segments are WuXi Chemistry, which derives maximum revenue, WuXi Testing, WuXi Biology, and Others. Geographically, it derives key revenue from the United States of America, followed by PRC, Europe, and other regions.
84GF Score
Get the complete analysis for WUXIF
Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WUXIF has been successfully added to your 
